Manistique
Manistique
Manistique, Michigan, United States10 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Classic Follicular Lymphoma; Follicular Lymphoma With Unusual Cytological Features | Recruiting | Phase 3 | 2026-10-09 | NCT06337318 | |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma | Recruiting | Phase 3 | 2026-10-09 | NCT06058377 | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, endometrium neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive organ cancer, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, uterine disorder | Recruiting | Phase 2 | 2026-10-08 | NCT05564377 | |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-07 | NCT06649812 | |
| Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | Cigarette Smoking-Related Carcinoma | Recruiting | Phase 3 | 2026-10-05 | NCT05008848 | |
| Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, appendiceal neoplasm, appendix carcinoma, carcinoma of esophagus, carcinoma of the ampulla of vater, cecal disorder, cecal neoplasm, colon carcinoma, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system cancer, digestive system disorder, digestive system neoplasm, esophageal disorder, gastric carcinoma, gastric neoplasm, intestinal disorder, neoplasm, rectal carcinoma, rectal disorder, rectal neoplasm, small intestine carcinoma, stomach disorder | Recruiting | Not applicable | 2026-10-02 | NCT07283939 | |
| Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube neoplasm, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian clear cell adenocarcinoma, ovarian disorder, ovarian seromucinous carcinoma, ovarian serous tumor, ovarian transitional cell carcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 3 | 2026-10-01 | NCT02446600 | |
| Mobile Health for Adherence in Breast Cancer Patients | Neoplasms by Site, Skin and Connective Tissue Diseases, breast carcinoma, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-09-04 | NCT06112613 | |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-02 | NCT05879926 | |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Adnexal Diseases, Bartholin gland transitional cell carcinoma, Biliary Tract Neoplasms, Carcinoma, Endometrioid, Cystadenocarcinoma, Serous, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Gestational Trophoblastic Disease, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Fibrous Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Nose Neoplasms, Otorhinolaryngologic Neoplasms, Parathyroid Neoplasms, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Pharyngeal Diseases, Pregnancy Complications, Neoplastic, Rare Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, acinar cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, adrenal gland pheochromocytoma, angiosarcoma, apocrine sweat gland neoplasm, basal cell carcinoma, basal cell neoplasm, bile duct disorder, bile duct neoplasm, biliary tract disorder, bladder adenocarcinoma, carcinoma, carcinosarcoma, cervical adenocarcinoma, cholangiocarcinoma, chordoma, colorectal squamous cell carcinoma, connective tissue neoplasm, cystadenocarcinoma, cystic, mucinous, and serous neoplasm, desmoid tumor, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrial transitional cell carcinoma, endometrium neoplasm, epithelial neoplasm, extrahepatic bile duct carcinoma, extramammary Paget disease, fallopian tube adenocarcinoma, fallopian tube transitional cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, fibroma, fibromyxoid tumor, fibrosarcoma, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, gastric squamous cell carcinoma, gastrointestinal stromal tumor, germinoma, gestational trophoblastic neoplasm, gonadal disorder, intrahepatic cholangiocarcinoma, lung adenocarcinoma, lung giant cell carcinoma, lung neoplasm, lung neuroendocrine neoplasm, lung sarcomatoid carcinoma, major salivary gland carcinoma, malignant endocrine neoplasm, minimally invasive lung adenocarcinoma, mixed neoplasm, mouth disorder, mucinous adenocarcinoma, mucinous adenocarcinoma of the appendix, mucinous cystadenocarcinoma, nasal cavity adenocarcinoma, nasal cavity carcinoma, nasal disorder, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, nerve sheath neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, neurofibroma, neurofibrosarcoma, neuromuscular disease, oral cavity carcinoma, otorhinolaryngologic disease, ovarian adenocarcinoma, ovarian cancer, ovarian disorder, ovarian germ cell tumor, ovarian mucinous adenocarcinoma, ovarian squamous cell carcinoma, ovarian transitional cell carcinoma, pancreas disorder, pancreatic acinar cell carcinoma, pancreatic endocrine carcinoma, pancreatic neoplasm, paraganglioma, paranasal sinus carcinoma, paranasal sinus disorder, paranasal sinus neoplasm, parathyroid gland carcinoma, parathyroid gland disorder, peripheral nervous system disorder, peripheral nervous system neoplasm, pheochromocytoma, placental choriocarcinoma, pregnancy disorder, primitive neuroectodermal tumor, pseudomyxoma peritonei, respiratory system disorder, respiratory tract neoplasm, sarcoma, scrotum squamous cell carcinoma, seminal vesicle adenocarcinoma, seminoma, small intestine adenocarcinoma, somatostatinoma, spindle cell neoplasm, squamous cell carcinoma of penis, squamous cell carcinoma of the small intestine, testicular non-seminomatous germ cell tumor, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor, trachea carcinoma, transitional cell carcinoma, trophoblastic neoplasm, undifferentiated carcinoma of esophagus, undifferentiated carcinoma of nasopharynx, undifferentiated carcinoma of stomach, ureter adenocarcinoma, ureter squamous cell carcinoma, urethra adenocarcinoma, urethra squamous cell carcinoma, vaginal adenocarcinoma, vascular cancer, vulva cancer, vulvar carcinoma, vulvar disease | Active, not recruiting | Phase 2 | 2026-06-17 | NCT02834013 |